Navigation Links
Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
Date:3/25/2013

EXTON, Pa., March 25, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceuticals issues, finds that, despite the 2012 launch of Medivation/Astellas Pharma's Xtandi (enzalutamide) for the treatment of docetaxel-pretreated metastatic castrate-resistant prostate cancer (mCRPC), surveyed oncologists report that Johnson & Johnson/Janssen Biotech/Janssen-Cilag's Zytiga continues to dominate the second-line mCRPC setting—although its share dropped marginally from Q3 2012 to Q1 2013. The patient share of Sanofi's Jevtana showed a marked decline over this time period as a result of Xtandi's availability, especially in the third line where Jevtana's patient share in Q1 2013 is half that of its reported share in Q3 2012. The findings are from the TreatmentTrends® Prostate Cancer (US) Q1 2013 report, in which 53 urologists and 51 medical oncologists were surveyed about their current and expected treatment practices for prostate cancer.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

"In the first-line symptomatic mCRPC setting, docetaxel still dominates treatment according to surveyed oncologists, despite the recent label extension of Zytiga for chemotherapy-naive mCRPC in December 2012," said Decision Resources Group Analyst Khurram Nawaz , M.Sc. "Nevertheless, surveyed oncologists indicate that Zytiga's patient share for first-line symptomatic mCRPC has almost doubled from Q3 2012 to Q1 2013. Interestingly, both surveyed urologists and oncologists indicate that Xtandi is also prescribed for first-line mCRPC patients, although this off-label use remains minimal due to perceived reimbursement challenges."

Surveyed physicians are most satisfied with Zytiga as a treatment for mCRPC; Dendreon's Pr
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Global Spinal Nonfusion Market to Grow to $1 Billion by 2017, Despite Challenges
2. Opportunities Exist Despite Challenges in Chinas API Market
3. Accelerating Drugs to Market - Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market
4. According to New Survey, Most Men are Not Proactive about Their Health Despite the Desire to Live Long Lives
5. SafeCode Drug Technologies Initiating Activities to Commercialize its Recent Newly Acquired Technology of the Pain-Free Injection
6. Precision Optics Corporation, Inc. Operating Results for Six Months Ended December 31, 2012 and Recent Operating Activities
7. Vancouver General Hospital Deploys TRU-D Superbug Slayer to Battle Worst Season of Flu in Recent Memory
8. KemPharm Supports Recent FDA Recommendations for Hydrocodone-Containing Compounds and Abuse-Deterrent Opioids
9. Hologic to Showcase 3D Mammography and Other Recent Innovations in Healthcare at the 38th Arab Health Congress in Dubai
10. Starkey Hearing Foundation Founders Bill and Tani Austin Honored by Dalai Lama After Recent Hearing Mission to India
11. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... today announced it has established a relief fund ... that has gripped much of the nation. AARP and its ... support these emergency relief efforts AARP and AARP Foundation will ... to $500,000 in aid. The matching program will be administered ...
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
(Date:4/22/2014)... spending, a new RAND study concludes that U.S. policy ... and device makers to develop products that produce more ... their use, a new study suggests the study identifies ... created in the first place. The aim is to ... of health as possible and to ensure that costlier ...
(Date:4/22/2014)... researchers have demonstrated the first size-based form of ... membranes of living cells. This unique physical approach ... critical to whether a cell lives or dies, ... obtained through conventional microscopy. , "We,ve developed membrane-embedded ... to both probe and manipulate membrane assemblies, including ...
(Date:4/22/2014)... been approved since November 2013 for the prevention and ... an early benefit assessment pursuant to the "Act on ... the German Institute for Quality and Efficiency in Health ... an added benefit over the appropriate comparator therapy. ... turoctocog alfa is not proven. As no relevant study ...
(Date:4/22/2014)... chronic inflammatory disorders of the intestine that result in ... in the U.S., and while there are treatments to ... , Now, Cincinnati Cancer Center and University of Cincinnati ... in her lab have done what is believed to ... important function for the Ron receptor, a cell surface ...
(Date:4/22/2014)... of us have gotten stuck in a check-out line ... Mather, assistant professor of physics and an instructor with ... or queues, has been crucial in trying to understand ... of proteins. , The work, submitted during Mather,s first ... the National Science Foundation in the form of a ...
Breaking Medicine News(10 mins):Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:First size-based chromatography technique for the study of livi 2Health News:First size-based chromatography technique for the study of livi 3Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 3Health News:Two genes linked to inflammatory bowel disease 2Health News:Queuing theory helps physicist understand protein recycling 2
... 15 Theranostics Health (THX) today,announced that ... research,collaboration agreement with Duke University. This relationship ... core technologies: Laser,Capture Microdissection (LCM) and Reverse ... these technologies provides a powerful,mechanism to accurately ...
... Corporation, a,subsidiary of Orthopedic Development Corporation, announced today ... treat chronic facet-oriented back,pain or to supplement other ... of the two facet joints in each spinal ... treat intractable back pain without,precluding other options, has ...
... Health Solutions, Corp.,("SXC" or the "Company") (NASDAQ: SXCI ... services, announces that Mark Thierer,President and COO and Jeff ... Capital Markets 12th Annual Spring Investor Conference at the ... on Thursday, May 29,2008 at 10:30 am Eastern Time., ...
... important as intervention, specialists say , , THURSDAY, May 15 ... such as pacemakers and defibrillators emphasize that they,re just ... very specific statement of the importance of optimized medical ... University of Alabama at Birmingham,s Division of Cardiovascular Disease, ...
... American College of Physicians (ACP) proposed today a ... and use of information about clinical and cost-effectiveness ... The recommendations are featured in an article, Cost-Effectiveness ... Effectiveness Entity, published online today in Annals of ...
... BIRMINGHAM, Ala., May 15 Diagnostic Health Corporation,(DHC), ... the appointment of Robert E. Gontarek as its ... this role, Gontarek will oversee,the operations of DHC,s ... Gontarek joins DHC with nearly 20 years ...
Cached Medicine News:Health News:Theranostics Health Signs Research Collaboration Agreement 2Health News:TruFUSE(R) Minimally Invasive Facet Fusion Procedure Tops 3,000 Spinal Levels 2Health News:New Guidelines Issued for Implanted Heart Devices 2Health News:Americans must consider cost and effectiveness when comparing and choosing medical interventions 2Health News:Diagnostic Health Corporation Names Robert E. Gontarek as COO 2
... A stethoscope adapter for users of ... and socket" type - must send ... are required. , ,Westone custom ... via our worldwide network of hearing ...
... bronchoscopy: The HF-compatible V series from Pentax, ... bronchoscopes are measured., ,The HF-compatible series ... FB-19TV, FB-18V and FB-15V models along with ... FB-8V, offer much better image quality thanks ...
... from the latest 60 series bronchoscopes., ... range, focussing on providing clinicians with ... Olympus has a impressive range of ... in the respiratory tract to meet ...
Extra-large 3.2mm channel allows excellent suction with EndoTherapy devices in place....
Medicine Products: